Mr. Jim Breslin:

That forms part of our contingency planning. That is why we can talk about no immediate issues. Up to 15% of our volumes of cancer compounded products come from the United Kingdom. That means that 85% originate here. We will seek to boost that figure. We have facilities, including in public hospitals, where over time and with other strategies we can seek to boost it. We will also seek to husband the product to ensure it is managed as efficiently as possible. It is all built on the interrogation of suppliers coming across the Irish Sea and the resilience of their supply chains, as well as their contingency planning. These are our contingency plans. They just do not operate on the basis that we hope everything will go well. We scenario-plan them such that if three or four issues go against us, we will have a further back-up plan.